Photothermal Therapy with HER2-Targeted Silver Nanoparticles Leading to Cancer Remission

Victoria O. Shipunova, Mariia M. Belova, Polina A. Kotelnikova, Olga N. Shilova, Aziz B. Mirkasymov, Natalia V. Danilova, Elena N. Komedchikova, Rachela Popovtzer, Sergey M. Deyev, Maxim P. Nikitin

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Nanoparticles exhibiting the localized surface plasmon resonance (LSPR) phenomenon are promising tools for diagnostics and cancer treatment. Among widely used metal nanoparticles, silver nanoparticles (Ag NPs) possess the strongest light scattering and surface plasmon strength. However, the therapeutic potential of Ag NPs has until now been underestimated. Here we show targeted photothermal therapy of solid tumors with 35 nm HER2-targeted Ag NPs, which were produced by the green synthesis using an aqueous extract of Lavandula angustifolia Mill. Light irradiation tests demonstrated effective hyperthermic properties of these NPs, namely heating by 10 °С in 10 min. To mediate targeted cancer therapy, Ag NPs were conjugated to the scaffold polypeptide, affibody ZHER2:342, which recognizes a clinically relevant oncomarker HER2. The conjugation was mediated by the PEG linker to obtain Ag-PEG-HER2 nanoparticles. Flow cytometry tests showed that Ag-PEG-HER2 particles successfully bind to HER2-overexpressing cells with a specificity comparable to that of full-size anti-HER2 IgGs. A confocal microscopy study showed efficient internalization of Ag-PEG-HER2 into cells in less than 2 h of incubation. Cytotoxicity assays demonstrated effective cell death upon exposure to Ag-PEG-HER2 and irradiation, caused by the production of reactive oxygen species. Xenograft tumor therapy with Ag-PEG-HER2 particles in vivo resulted in full primary tumor regression and the prevention of metastatic spread. Thus, for the first time, we have shown that HER2-directed plasmonic Ag nanoparticles are effective sensitizers for targeted photothermal oncotherapy.

Original languageEnglish
Article number1013
JournalPharmaceutics
Volume14
Issue number5
DOIs
StatePublished - May 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Funding

Funding: This research was partially supported by Russian Science Foundation, grant number 17-74-20146 (in vivo study), and the grants of Russian Foundation for Basic Research: number 20-04-60552 (nanoparticle surface modification), 20-34-90029 (cell culture), and the joint grant of the Russian Foundation for Basic Research 19-515-06010 and Israel Ministry of Science and Technology 3-16491 (nanoparticle characterization).

FundersFunder number
Russian Foundation for Basic Research20-04-60552, 20-34-90029, 19-515-06010
Ministry of science and technology, Israel
Russian Science Foundation17-74-20146

    Keywords

    • Ag
    • HER2
    • affibody
    • green synthesis
    • local hyperthermia
    • photothermal therapy
    • silver nanoparticles
    • targeted delivery

    Fingerprint

    Dive into the research topics of 'Photothermal Therapy with HER2-Targeted Silver Nanoparticles Leading to Cancer Remission'. Together they form a unique fingerprint.

    Cite this